The Isis Group is a life sciences consulting and grant assistance company. We have helped biotech startups developing therapeutics, diagnostics, medical devices or healthcare IT solutions obtain millions of dollars in non-dilutive funding through the SBIR/STTR program and other grant (R21, R01, P01) or contract mechanisms from the NIH, NSF, USDA, CDC, FDA, CDMRP, and DoD as well as private foundations.

Extend Biosciences is a clinical-stage biotechnology company with a novel drug delivery platform D-VITylation(TM) that harnesses the biology of vitamin D to extend the half-life and improve the subcutaneous bioavailability of therapeutic peptides and proteins.Extend Biosciences was a finalist in the MassChallenge global startup competition and a semi-finalist in the WPI Venture Forum business plan competition. Since then, we have raised >$20M in non-dilutive funding, primarily from state (MLSC, MassVentures) and federal grant programs, including SBIR Phase I, II and IIB, and R01 grants from NIH, FDA, NSF and the DoD.In addition to building the D-VITylation platform, we currently have multiple peptides under development in the disease areas of diabetes, cardiovascular disease, muscle wasting diseases and cancer supportive care (cachexia). Our lead program, a D-VITylated PTH, is currently in Phase 2 clinical trials for the rare disease hypoparathyroidism.

I served on the Interdisciplinary Molecular Sciences and Training [IMST] Diabetes, Metabolism, Nutrition and Obesity review panel, and the IMST Basic and Integrative Bioengineering IRG review panel for Small Business SBIR/STTR grants submitted to NIH. I also review grant applications through the Center for Technology Commercialization (U. Wisconsin), the Massachusetts Association of Technology Transfer Offices (MATTO), ACORN Awards, MassVentures START and Inspiralia.

Professional scientific editor, providing English language editing assistance to scientific professionals worldwide. Proofread, revise and edit scientific and medical documentation written by international authors. Copyedit proofs for major scientific journals.

Tracertech was a pre-seed start-up nanotechnology company focused on providing a simple way to curb the rampant abuse of drugs used for athletic performance enhancement.Developed strategic plan, co-wrote business plan and presented to investor groups, applied for competitive research grants, identified collaborations with academia and CROs.

Neotropix is a start-up biotechnology company dedicated to the development and commercialization of virus-based therapeutics for the treatment of cancer and other diseases.Group Leader, 2005-2007Senior Scientist, 2005Designed and directed preclinical studies on an oncolytic virus leading to a successful IND filing in just 13 months from company inception. Led a matrix-based project team and discovered four candidate biomarkers for a clinical assay to prescreen small cell lung cancer patients in a Phase II trial.

Purdue Pharma, L.P. is a start-up venture funded by a privately-held pharmaceutical company aimed at the discovery and development of novel immunotherapeutics for cancer and new molecular entities to treat pain.Senior Research Investigator, 2002-2004Research Investigator, 1999-2002Researched and validated passive and active immunotherapy targets, and led cross-disciplinary project teams to develop therapeutic antibodies and cancer vaccines.